MTIS 2022: Ongoing Study Evaluating Efficacy of Migraine Prevention in Patients With Depressionn
UNITE study examining efficacy and safety of fremanezumab with comorbid episodic or chronic migraine and major depressive disorder
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.